IL278418B2 - Vaccine composition - Google Patents

Vaccine composition

Info

Publication number
IL278418B2
IL278418B2 IL278418A IL27841820A IL278418B2 IL 278418 B2 IL278418 B2 IL 278418B2 IL 278418 A IL278418 A IL 278418A IL 27841820 A IL27841820 A IL 27841820A IL 278418 B2 IL278418 B2 IL 278418B2
Authority
IL
Israel
Prior art keywords
composition
kda
protein
seq
nucleic acid
Prior art date
Application number
IL278418A
Other languages
English (en)
Hebrew (he)
Other versions
IL278418B1 (en
IL278418A (cg-RX-API-DMAC10.html
Original Assignee
Spybiotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807378.3A external-priority patent/GB201807378D0/en
Priority claimed from GBGB1807376.7A external-priority patent/GB201807376D0/en
Application filed by Spybiotech Ltd filed Critical Spybiotech Ltd
Publication of IL278418A publication Critical patent/IL278418A/en
Publication of IL278418B1 publication Critical patent/IL278418B1/en
Publication of IL278418B2 publication Critical patent/IL278418B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL278418A 2018-05-04 2019-05-03 Vaccine composition IL278418B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1807378.3A GB201807378D0 (en) 2018-05-04 2018-05-04 Vaccine composition
GBGB1807376.7A GB201807376D0 (en) 2018-05-04 2018-05-04 HMCV Vaccine Composition
PCT/GB2019/051245 WO2019211630A2 (en) 2018-05-04 2019-05-03 Vaccine composition

Publications (3)

Publication Number Publication Date
IL278418A IL278418A (cg-RX-API-DMAC10.html) 2020-12-31
IL278418B1 IL278418B1 (en) 2023-09-01
IL278418B2 true IL278418B2 (en) 2024-01-01

Family

ID=66484095

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278418A IL278418B2 (en) 2018-05-04 2019-05-03 Vaccine composition

Country Status (11)

Country Link
US (2) US12433944B2 (cg-RX-API-DMAC10.html)
EP (1) EP3787676A2 (cg-RX-API-DMAC10.html)
JP (2) JP7575096B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210013571A (cg-RX-API-DMAC10.html)
CN (2) CN112638411B (cg-RX-API-DMAC10.html)
AU (2) AU2019263706B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020022393A2 (cg-RX-API-DMAC10.html)
CA (1) CA3099381A1 (cg-RX-API-DMAC10.html)
IL (1) IL278418B2 (cg-RX-API-DMAC10.html)
SG (1) SG11202010821TA (cg-RX-API-DMAC10.html)
WO (1) WO2019211630A2 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433944B2 (en) * 2018-05-04 2025-10-07 SpyBiotech Limited Vaccine composition
GB201917265D0 (en) * 2019-11-27 2020-01-08 Univ Sheffield Bonded neurotoxins
AU2020402106A1 (en) 2019-12-11 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mumps and Measles virus immunogens and their use
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
WO2022129547A1 (en) * 2020-12-18 2022-06-23 University Of Copenhagen Nucleic acid vaccines
US20240240203A1 (en) * 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
US20250157651A1 (en) * 2022-01-19 2025-05-15 Trustees Of Dartmouth College Systems and methods for deterring viral transmission using neural networks
US12492266B2 (en) 2022-02-21 2025-12-09 Youcare Pharmaceutical Group Co., Ltd. Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and use thereof
CN115920026B (zh) * 2022-04-02 2023-11-14 中山大学 耐热性多聚体蛋白支架、耐热性多聚体蛋白支架在疫苗中的应用
CN115010812B (zh) * 2022-04-12 2024-06-21 河南省龙星生物科技有限公司 一种非洲猪瘟抗原介导细胞免疫的多聚体及应用
CN116041536A (zh) * 2022-09-15 2023-05-02 山西大学 一种多接头自组装蛋白纳米颗粒的制备方法与应用
CN117462666B (zh) * 2022-09-30 2024-07-30 烟台派诺生物技术有限公司 一种预防或治疗水痘-带状疱疹病毒相关疾病的免疫组合物产品及其制备方法
CN117264074A (zh) * 2023-01-12 2023-12-22 东沃同泰(凤城)生物工程有限公司 靶向DCs递送的耐热性纳米颗粒蛋白、纳米载体、免疫原性复合物和纳米颗粒疫苗及应用
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
CN117264081B (zh) * 2023-11-21 2025-03-21 华南理工大学 一种双肽受体激动剂及其制备方法与应用
CN118373888B (zh) * 2024-06-27 2024-08-30 普大生物科技(泰州)有限公司 一种水痘-带状疱疹病毒纳米颗粒蛋白及其制备方法和应用
WO2026028158A1 (en) * 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Targeted degradation of anti-aav antibodies to enable aav-based gene therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) * 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
WO2011009877A1 (de) 2009-07-24 2011-01-27 Basf Se Flammgeschützte polyamidformmassen
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
EP2614072A4 (en) 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
JP6232544B2 (ja) 2011-11-11 2017-11-22 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法
AU2013286093B2 (en) 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
GB201509782D0 (en) 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN115960263A (zh) 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
CN106081304A (zh) 2016-07-27 2016-11-09 佛山市高明金荣华乐金属制品有限公司 一种新型可折叠箱体及其拆装方法
GB201705750D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd Peptide ligase and use therof
GB201706430D0 (en) 2017-04-24 2017-06-07 Univ Oxford Innovation Ltd Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
US12433944B2 (en) 2018-05-04 2025-10-07 SpyBiotech Limited Vaccine composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) * 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FELIX WUSSOW ET AL:, HUMAN CYTOMEGALOVIRUS VACCINE BASED ON THE ENVELOPE GH/GL PENTAMER COMPLEX, 20 November 2014 (2014-11-20) *
GORDON JOYCE ET AL:, ITERATIVE STRUCTURE-BASED IMPROVEMENT OF A FUSION- GLYCOPROTEIN VACCINE AGAINST RSV, 1 September 2016 (2016-09-01) *
KARL D. BRUNE ET AL:, PLUG-AND-DISPLAY: DECORATION OF VIRUS-LIKE PARTICLES VIAISOPEPTIDE BONDS FOR MODULAR IMMUNIZATION, 19 January 2016 (2016-01-19) *
MICHEL ET AL:, OPTIMISATION OF SECRETION OF RECOMBINANT HBSAG VIRUS-LIKE PARTICLES: IMPACT ON THE DEVELOPMENT OF HIV-1/HBV BIVALENT VACCINES, 31 January 2007 (2007-01-31) *
VEGGIANI GIANLUCA ET AL:, VEGGIANI GIANLUCA ET AL: " SUPERGLUE FROM BACTERIA: UNBREAKABLE BRIDGES FOR PROTEIN NANOTECHNOLOGY" ,TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, VOL. 32, NO. 10, 26 AUGUST 2014 (2014-08-26), PAGES 506-512, 28 August 2014 (2014-08-28) *

Also Published As

Publication number Publication date
WO2019211630A2 (en) 2019-11-07
US20260007740A1 (en) 2026-01-08
JP2021523937A (ja) 2021-09-09
CN112638411A (zh) 2021-04-09
JP2024156964A (ja) 2024-11-06
BR112020022393A2 (pt) 2021-02-02
AU2019263706B2 (en) 2026-02-26
WO2019211630A3 (en) 2019-12-05
JP7575096B2 (ja) 2024-10-29
KR20210013571A (ko) 2021-02-04
SG11202010821TA (en) 2020-11-27
IL278418B1 (en) 2023-09-01
AU2026201020A1 (en) 2026-03-05
CN120040601A (zh) 2025-05-27
US20210128717A1 (en) 2021-05-06
EP3787676A2 (en) 2021-03-10
JP7882546B2 (ja) 2026-06-30
US12433944B2 (en) 2025-10-07
AU2019263706A1 (en) 2020-11-19
CN112638411B (zh) 2025-03-04
CA3099381A1 (en) 2019-11-07
IL278418A (cg-RX-API-DMAC10.html) 2020-12-31

Similar Documents

Publication Publication Date Title
JP2024156964A5 (cg-RX-API-DMAC10.html)
JP2024156964A (ja) ワクチン組成物
JP2015509707A5 (cg-RX-API-DMAC10.html)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
GB2598494A (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
AU2013357367B2 (en) Modified coiled coil type proteins having improved properties
CN105960412A (zh) 作为疫苗平台的含鞭毛蛋白的蛋白纳米颗粒
JP2013503159A5 (cg-RX-API-DMAC10.html)
JP2014507146A5 (cg-RX-API-DMAC10.html)
JP2020516251A (ja) 結合および生物活性を改善した腫瘍壊死因子受容体(tnfr)結合タンパク質複合体
TW202130363A (zh) 變異型rsv f蛋白質及其利用
WO2022043449A1 (en) Vaccines based on an antigen protein fused to a nanostructuring scaffold
CN117279659A (zh) 人偏肺病毒疫苗
JP2023533871A5 (cg-RX-API-DMAC10.html)
JP6964518B2 (ja) ヤツメウナギ由来の配列への融合による組換えタンパク質の多量体化
JP2014530224A (ja) ノロウイルス感染に対するワクチンとしての自己集合ペプチドナノパーティクル
CN104755619A (zh) 用于预防猪水肿病的疫苗
CN1316431A (zh) 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
WO2024047090A3 (en) Modified virus-like particles of cmv
CN113939313B (zh) 以肽核酸为基础的佐剂
CN116813793B (zh) 融合蛋白以及其应用
CN112512552B (zh) 自组装肽支架
JP2025509352A5 (cg-RX-API-DMAC10.html)
JP2024024094A5 (cg-RX-API-DMAC10.html)
Gonçalves et al. Immunogen display on virus-like particles assembled from redesigned transcription activator-like effector proteins and nucleic acids: Activation of antigen-presenting cells